%PDF-1.4
%
86 0 obj
<>
endobj
146 0 obj
<>/Font<>>>/Fields[]>>
endobj
83 0 obj
<>
endobj
193 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-26T13:11:45Z
2024-03-29T00:44:53-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:44:53-07:00
application/pdf
Heather
201336.suppl.62
uuid:a860fdd6-1dd1-11b2-0a00-ba0927fd5800
uuid:a860fdd8-1dd1-11b2-0a00-6a0000000000
endstream
endobj
72 0 obj
<>
endobj
73 0 obj
<>
endobj
87 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
22 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
30 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
38 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
49 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
52 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
232 0 obj
[237 0 R]
endobj
233 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(multiple iv infusions of anti-tumor necrosis factor alpha)Tj
0 -1.25 TD
(monocloncal antibody combined with low-dose weekly)Tj
T*
[(methotrexate in rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1998;41:1552-63,)Tj
0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Maini R, St Clair EW)92 (, Breedveld F)80 (, et al. Infliximab \(chimeric anti-)]TJ
2.175 -1.25 Td
(tumour necrosis factor alpha monoclonal antibody\) versus placebo)Tj
T*
(in rheumatoid arthritis patients receiving concomitant methotrexate:)Tj
-0.00011 Tc T*
[(a randomised phase III trial. )55 (A)111 (TTRACT)-257 (Study Group. Lancet)]TJ
0 Tc 0 Tw T*
(1999;354:1932-9.)Tj
0.0249 Tw -2.175 -1.25 Td
[(28.)-875 (Kavanaugh )55 (A, St. Clair EW)92 (, McCune )18 (WJ, Braakman )18 (T)74 (, Lipsky P)111 (.)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Chimeric anti-tumor necrosis factor)20 (-alpha monocloncal antibody)]TJ
0 Tc T*
(treatment of patients with rheumatoid arthritis receiving)Tj
T*
[(methotrexate therapy)65 (. J Rheumatol 2000;27:841-50.)]TJ
-2.175 -1.25 Td
[(29.)-875 (Antoni C, Kalden JR. Combination therapy of the chimeric)]TJ
2.175 -1.25 Td
(monoclonal anti-tumor necrosis factor alpha antibody \(infliximab\))Tj
T*
(with methotrexate in patients with rheumatoid arthritis. Clin Exp)Tj
T*
(Rheumatol 1999;17 Suppl 18:S73-7.)Tj
-2.175 -1.25 Td
[(30.)-875 (Emery P)111 (, Panay G, Sturrock R, )18 (W)40 (illiams B. )18 (T)70 (ar)18 (geted therapies in)]TJ
2.175 -1.25 Td
(rheumatoid arthritis: the need for action. Rheumatology)Tj
0 Tw T*
[(1999;38:91)37 (1-6.)]TJ
-0.00011 Tc 0.02499 Tw 30.825 23.75 Td
[(31.)-875 (Matteson EL. Current treatment strategies for rheumatoid arthritis.)]TJ
0 Tc 2.175 -1.25 Td
(May Clin Proc 2000;75:69-74.)Tj
-2.175 -1.25 Td
[(32.)-875 (Lipsky PE, Kavanaugh )55 (A. )18 (The impact of pharmaco-economic)]TJ
2.175 -1.25 Td
(considerations on the utilization of novel anti-rheumatic therapies.)Tj
T*
(Rheumatology 1999;38 Suppl 2:41-4.)Tj
-2.175 -1.25 Td
[(33.)-875 (Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the)]TJ
-0.00011 Tc 2.175 -1.25 Td
(round-table discussion-assessing the role of anti-tumour necrosis)Tj
0 Tc T*
(factor therapy in the treatment of rheumatoid arthritis. Rheum)Tj
T*
(1999;38 Suppl 2:50-3.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(34.)-875 (Furst D, Breedveld FC, Kalden JR, Smolen JS. Building towards a)]TJ
2.175 -1.25 Td
(consensus for the use of tumour necrosis factor blocking agents.)Tj
0 Tc T*
(Ann Rheum Dis 1999;58:725-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875 (Smolen JS, Breedveld FC, Burmester)40 (, Combe B, Emery P)111 (, Kalden)]TJ
0 Tc 2.175 -1.25 Td
(JR. Consensus statement on the initiation and continuation of tumor)Tj
T*
[(necrosis factor flocking therapies in rheumatoid arthritis. )55 (Ann)]TJ
T*
(Rheum Dis 2000;59:504-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(36.)-875 (REMICADE\256)-275 (\(infliximab\) [prescribing information 1)37 (1/1999])]TJ
2.175 -1.25 Td
[(Centocor)40 (, Inc., Malvern, P)92 (A)-220 (19355.)]TJ
ET
0 0 0 0 scn
468 770 90 -25 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT1 1 Tf
0 Tc 8 0 0 8 54.5 35.9844 Tm
(Kalden: Biologics in therapy)Tj
0 Tw 61.9375 -0.0313 Td
(35)Tj
ET
0 0 0 0 scn
/GS0 gs
100.25 59.75 407.5 -10.83 re
f*
0.5 w
100.25 59.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
125 0 obj
<>
endobj
198 0 obj
<>
endobj
91 0 obj
<>
endobj
89 0 obj
<>
endobj
90 0 obj
<>
endobj
119 0 obj
<>stream
HV pUBBN&G@2E#fR5e@òErEɱ"DBI Ѫ-?f t@-{.o@E&cK*Uaf
y 틢Wͬ<#8 Ŝ@*.mae_AA!|{"P^SGbՈJª\:^_Yּ%kUs/nRݶj^Y߿dB:hr tV* XgHWH7S wH?QB=>,b_Ez"#X0E$<XA[H6TEb(/E5SCۿr<p18 荷p\|*:FzQeXkmCo`G%q?s$r]`ZN"\tD"xz!;M.&GZ`Fkl?Έr`Z{^?([<,u#&HjZVBCgwfb-61/p.-|\%SҫN5JnF"+$I%&?w^█=De|J9VUU%jd'd?":[Oda/3т;'4a`gqNFiU'K76UhYs9egnyL'R^n/a챔c%VΟpc8Cn6>QD(hȑ,ܬPv5_bK2(vaVr,bR')"p%IqƇԑujZmQiEZVd5߅*1#'mQrfouFf>O,fv'~]GP@sGpX*->@:x$0OVJZHqJkXI{N+}uZe|qWp1%+iwzZS=LIaƥw5!>.6&K':EuѾ]xӡH#|3c(~
?Lۘ/d?ne,="Jtk\CoSr&(͖zLhd\.z\>kx}XyW)Ҕ#e,ͪQ=3\^ThpmI^[⛥p"0ǚ'LLXڙi
LWȟ ӛdXf00{v-i^*?}yVM@gPh0W@JҌO`^0s|AvM(C h&q$G {i7ၡLK3SSsm"!A?wzըͮ,YGѠ[Ƀb2fV^Gqםdgk>Dؚ>qbfXOǨފA?겐:I[Kfyt^2oz+S kQ-,l
A]EyVFڧ/BfY7l{R )ԍ$II!
gH'0FΩH6Tbn~swROe
8{dV3H2~Ru۹UXvn$C"#Ju[k}q;D$}AN!~A6FO_#l休ԅT)b~*OWlS;%vNnL'&
6l*Af -I!iE[:`aaee@dRӂ4!-&mTss&3l#'+Vuiɕ
1g<,X83<@vxm%N*ۃ ̷4+f;Y>u}#S<|{=alC/=گG 7:$:>Qb?yy[; gv6]3I6%
#@4,vf#,X(y7YDuc^>DGptx?~2DȰ:!:WśM'@V N 2d (K'@:uWtdɏdtȨ^ Q'{2dud1F&.`#KhR&nJnmܚnSnS[HW֪ev+_u+Snn"A5[2Ѫ*J]U)ie
L
m+߄߇OHX
+Ua(3үW~ޯ+jOjBpk#7HYRa\=Oress><21:~!Yxd
Кxxd-.qu6XpRgRC!x)eqz7n@\V#oPpNʍ%a&+gxu?Eqz]pѣSZ:㙢7"o@vKrӟyxqw2SuHR|ǫÞ
r#{K6z7nNѵUUyv>rmrK!| 5ɧڤۚS%*xeYr&O}fE(u7nbERROmb?bj)L-bR@K69[6˙r&˲Qd¦'JZlF3#f,k2A'D29 vz ; /ΰd5'dwr7HHOCv3lLx!'G[pŇPnp-6b߹ni%,=ŗ;'IB⊖ qAbLb)5ze']X!h-ewq KBM㤞Q X=5\!?#ᓈ2s˺23YNrJvrE1K(%QqPJ2K<4zd1Oo=\l.͵ds342hGgeRƨc{Evdwlc IBH4J4ҌR\BaǛn3u(PgG0k~q?k.d'e7(D9Lm5uկN;OL$bg